Phaseline

Targets › SEMA3A

SEMA3A (Semaphorin-3A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2027.

Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. (UniProt, Q14563)

Open in Phaseline: the race on SEMA3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BayerBAY 3401016
Semaphorin 3A (Sema3A) antagonist monoclonal antibody
SEMA3APhase 2Alport SyndromeNov 2027

Conditions

Alport Syndrome (1)

Modalities

small molecule (1)

Companies

Bayer (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.